Nurix Therapeutics Inc

Several biotech stocks reached 52-week highs on August 7, 2026, driven by quarterly results and clinical advancements. Delcath Systems surged over 22% to $15.62 after reporting second-quarter net revenues of $29.1 million, up from $24.2 million a year earlier, with HEPZATO product revenue growing about 30% to $27.1 million across roughly 31 active treatment centers. Alto Neuroscience rose to a 52-week high of $29.48 following last month's registered direct offering that raised an estimated $100 million to advance its lead candidate ALTO-207 toward a Phase 3 trial. Hemab Therapeutics hit $53.60 after positive Phase 2 data showed Sutacimig reduced the mean annualized treated bleeding rate by 84% in Glanzmann thrombasthenia and Factor VIII deficiency, alongside encouraging interim Phase 2 results for HMB-002 in Von Willebrand's disease. Monopar Therapeutics reached $124.31 on the back of positive Phase 3 results for ALXN1840 in Wilson disease, which earned a Rare Pediatric Disease voucher from the FDA, with an NDA submission planned by mid-2026. Nurix Therapeutics climbed to $25.49 after receiving a $10 million milestone payment from Sanofi for the Phase 1 initiation of NX-3911 and announcing with Roche the first patient enrolled in the Phase 3 DAYBreak CLL-306 trial evaluating Bexobrutideg in relapsed/refractory chronic lymphocytic leukemia.

Nurix Therapeutics announced a $10 million milestone payment from Sanofi triggered by the first-in-human trial of an oral STAT6 degrader, bringing total receipts under that collaboration to about $139 million. The company also enrolled the first patient in a pivotal global Phase 3 trial of bexobrutideg for relapsed or refractory chronic lymphocytic leukemia, conducted in partnership with Roche. The Sanofi deal leaves Nurix eligible for roughly $453 million in additional milestones plus potential royalties, while the Roche-partnered study marks a move into registrational testing. Both programs advance Nurix's clinical pipeline in targeted protein degradation and signal that large pharmaceutical partners are committing resources to its drug candidates.

Nurix Therapeutics has enrolled the first patient in its registrational Phase 3 DAYBreak CLL-306 trial evaluating bexobrutideg, a BTK degrader, in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who previously received a covalent BTK inhibitor. The global study, conducted in collaboration with Roche, is designed to demonstrate superiority of bexobrutideg versus the non-covalent BTK inhibitor pirtobrutinib, the current standard of care in this setting. Approximately 620 patients will be randomized 1:1 to receive either bexobrutideg 600 mg orally once daily or pirtobrutinib, with dual primary endpoints of objective response rate and progression-free survival assessed by an independent review committee. This marks the first Phase 3 trial for bexobrutideg and is part of a broader clinical development program that includes a pivotal Phase 2 study and other combination trials.

A new competitive landscape report from DelveInsight reveals that more than 80 active pharmaceutical companies are developing over 90 pipeline molecular glues, with approximately 7 therapies in late-stage development and 15 in mid- or early-stage trials. Key players include Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, Nurix Therapeutics, Monte Rosa Therapeutics, and Neomorph, among others, evaluating candidates such as Daraxonrasib, GT919, CT-01, and NEO-811. The report highlights notable mechanisms of action including RAS(ON) inhibition, GSPT1 degradation, and c-Myc degradation, and covers recent milestones like the FDA’s Breakthrough Therapy Designation for Daraxonrasib and the first patient dosing in Degron Therapeutics’ Phase 1 trial of DEG6498. Approved molecular glues POMALYST and REVLIMID from Bristol Myers Squibb are also profiled, underscoring the class’s established role in multiple myeloma and other hematologic malignancies.

Nurix Therapeutics has closed its global collaboration agreement with Roche to co-develop and co-commercialize Bexobrutideg following the expiration of the Hart-Scott-Rodino waiting period. Nurix will receive an upfront cash payment of $700 million and is eligible for milestone payments that could bring total potential payments to up to $2.3 billion. The companies will share development costs with Nurix covering 40 percent and Roche covering 60 percent, and they will equally split profits and losses from U.S. commercialization. Outside the United States, Roche will handle commercialization and Nurix will receive royalties ranging from the low to high teens. Bexobrutideg is currently in Phase 2 and Phase 1 trials for certain blood cancers, with additional Phase 3 and combination trials planned.

Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize its BTK degrader bexobrutideg, with potential total payments of up to $2.3 billion including a $700 million upfront payment. The agreement covers malignant hematology, immunology, and neurology, with development costs shared 40% by Nurix and 60% by Roche, and profits and losses in the United States shared equally. Nurix also reported updated clinical data at the European Hematology Association meeting showing an 83% objective response rate in relapsed/refractory CLL patients and a 92.9% response rate in a BTK inhibitor-pretreated, BCL2 inhibitor-naïve cohort. As of May 31, 2026, Nurix had cash, cash equivalents, and marketable securities of $443.5 million, with pro-forma cash of approximately $1.14 billion including the expected upfront payment. The company reported a net loss of $89.5 million for the fiscal second quarter of 2026.

Baird raised its price target on Nurix Therapeutics to $33 from $26 while maintaining an Outperform rating, citing the company's partnership with Roche and continued clinical progress. The firm updated its valuation to reflect the collaboration. Nurix recently reported updated Phase 1a/b data for its oral BTK degrader bexobrutideg in chronic lymphocytic leukemia, showing an 83% objective response rate in relapsed/refractory patients and a median progression-free survival of 22.1 months. The therapy demonstrated a favorable safety profile with no dose-limiting toxicities or treatment-related Grade 5 adverse events across 142 patients. A Phase 3 monotherapy program is planned.

Shares of Nurix Therapeutics have rallied 28.6% over the past month, driven by investor optimism around its newly signed exclusive licensing and collaboration agreement with Roche. Under the deal, the companies will co-develop and co-commercialize Nurix's lead pipeline candidate, bexobrutideg, across malignant hematology, immunology, and neurology indications. Nurix will receive $700 million upfront and could earn up to $2.3 billion in total milestone payments, while Roche will cover 60% of development costs and Nurix will fund the remaining 40%. The two firms will equally share U.S. profits and losses, and Nurix will receive tiered royalties ranging from low to high-teens on ex-U.S. sales. Bexobrutideg is an oral BTK degrader expected to enter phase III testing in second-line chronic lymphocytic leukemia later in 2026, with additional phase II studies planned in multiple sclerosis and chronic spontaneous urticaria.

Nurix Therapeutics shares touched a 52-week high of $23.09 on Thursday, extending a winning streak to an eighth straight session, after the company announced a partnership with Roche to co-develop the blood cancer treatment bexobrutideg. The collaboration covers a clinical development plan across malignant hematology, immunology, and neurology, including Phase 2 and Phase 3 trials in chronic lymphocytic leukemia and expansion into immune-mediated diseases such as multiple sclerosis and chronic spontaneous urticaria. Under the agreement, Nurix will receive $700 million in upfront cash and is eligible for up to $2.3 billion in milestone payments. The stock closed at $22.46, up 16.37 percent.

The chronic spontaneous urticaria market across the seven major markets reached approximately 2 billion dollars in 2025, with the United States holding the largest share. Total diagnosed prevalent cases of chronic urticaria in those markets were about 4.8 million in 2025 and are expected to rise by 2036. Key companies advancing new therapies include Celldex Therapeutics, Sanofi, Jasper Therapeutics, Evommune, Blueprint Medicines, ARS Pharmaceuticals, Nurix Therapeutics, InflaRx, and Otsuka Holdings through Taiho Pharmaceutical. Promising pipeline candidates such as barzolvolimab, rilzabrutinib, briquilimab, EVO756, BLU-808, ARS-1, bexobrutideg, INF904, and TAS5315 are in clinical development, while recent approvals of DUPIXENT and RHAPSIDO have already broadened treatment options beyond traditional anti-IgE biologics.